Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Relay Therapeutics ( (RLAY) ) is now available.
On June 3, 2025, Relay Therapeutics, Inc. announced a lease amendment with ARE MA Region No. 58, LLC, which will accelerate the termination of its Binney Street Lease in Cambridge, Massachusetts. This strategic move involves transitioning to a smaller office space at Kendall Square, resulting in a significant reduction of approximately $16 million in rent expenses over the lease commitments. The company continues to maintain its corporate headquarters at 60 Hampshire Street, Cambridge.
The most recent analyst rating on (RLAY) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.
Spark’s Take on RLAY Stock
According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.
Relay Therapeutics faces significant financial challenges, with consistent losses and negative cash flow impacting its financial performance. Technical indicators suggest a bearish trend, and valuation metrics highlight difficulties due to a negative P/E ratio. The absence of earnings call and corporate event data leaves these areas unaddressed in the score.
To see Spark’s full report on RLAY stock, click here.
More about Relay Therapeutics
Relay Therapeutics, Inc. operates in the biotechnology industry, focusing on developing precision medicines for cancer and genetic diseases. The company leverages its proprietary Dynamo platform to integrate computational and experimental approaches, aiming to transform the drug discovery process.
Average Trading Volume: 2,496,619
Technical Sentiment Signal: Sell
Current Market Cap: $545.2M
See more data about RLAY stock on TipRanks’ Stock Analysis page.